Dyadic International, Inc. (DYAI)
- Previous Close
2.2000 - Open
2.1700 - Bid 1.9600 x 100
- Ask 2.1200 x 100
- Day's Range
1.9100 - 2.2300 - 52 Week Range
1.1900 - 2.6700 - Volume
279,258 - Avg. Volume
82,811 - Market Cap (intraday)
59.058M - Beta (5Y Monthly) 0.90
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2800 - Earnings Date Aug 7, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
www.dyadic.comRecent News: DYAI
Performance Overview: DYAI
Trailing total returns as of 6/7/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DYAI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DYAI
Valuation Measures
Market Cap
59.06M
Enterprise Value
52.97M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
25.81
Price/Book (mrq)
13.08
Enterprise Value/Revenue
23.49
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-40.56%
Return on Equity (ttm)
-102.46%
Revenue (ttm)
2.26M
Net Income Avi to Common (ttm)
-7.85M
Diluted EPS (ttm)
-0.2800
Balance Sheet and Cash Flow
Total Cash (mrq)
12.04M
Total Debt/Equity (mrq)
131.82%
Levered Free Cash Flow (ttm)
-3.06M